Cipla USA, Inc. recalls Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactur
Recalled January 21, 2026 · FDA recall D-0290-2026 · Cipla USA
Hazard
Presence of Particulate Matter. · FDA Class II
Units
15,221 syringes
Sold at
Nationwide in the USA
Description
Presence of Particulate Matter.
Product
Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67
Manufacturer(s)
Cipla USA, Inc.
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →